Trial Profile
A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals; Lopinavir/ritonavir
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SWITCHMRK-1
- Sponsors Merck Sharp & Dohme
- 15 Jun 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.
- 13 Jan 2010 Results were published in 'The Lancet'.
- 17 Dec 2009 Patient numbers amended from 340 to 352 as reported by ClinicalTrials.gov.